1.Integrative Medicine for Cancer Patients.
Hanyang Medical Reviews 2010;30(2):126-135
Majority of cancer patients used CAM modalities during and even after cancer treatment. Main reasons for CAM use are to improve immunity, with expectation of fewer recurrences, and to have better quality of life. Still many patients did not reveal precise detailed information of CAM use to their physicians. Due to possible interaction between herbs and cancer drugs, it is essential for physicians to know whether their patients use CAM modalities or not and to have interest in existing evidence. This article will provide the lists of evidence and references on supplements and life styles including diet and exercise. Mind body medicine is not commonly used in Korea but there is increasing evidence on meditation and usefulness with relaxation even in supportive care.
Diet
;
Humans
;
Integrative Medicine
;
Korea
;
Life Style
;
Meditation
;
Mind-Body Therapies
;
Quality of Life
;
Recurrence
;
Relaxation
2.Stereotactic body radiotherapy for solitary spine metastasis.
Sunyoung LEE ; Mison CHUN ; Mijo LEE
Radiation Oncology Journal 2013;31(4):260-266
A clear consensus has not been established regarding the best treatment for solitary bone metastasis. Here, we reviewed the medical records of patients with a controlled primary malignancy who had only solitary spine metastasis without metastasis to the extraspinal bone or viscera and underwent treatment between April 2007 and December 2012 with stereotactic body radiosurgery using CyberKnife, with a total dose of 24 Gy in three to four fractions. During that time, there were only four cases. This was effective in each case, and all the four patients had no local failure and remained alive at a median follow-up of 68 months (range, 64 to 80 months). Although our experience is limited, this study suggests that stereotactic body radiotherapy could be a feasible, safe, effective, and noninvasive alternative treatment for solitary spine metastasis in patients who are medically inoperable or unsuitable for surgery.
Consensus
;
Follow-Up Studies
;
Humans
;
Medical Records
;
Neoplasm Metastasis*
;
Radiosurgery*
;
Spine*
;
Viscera
3.Time for global efforts with clinical trials for advanced cervical cancer patients.
Journal of Gynecologic Oncology 2009;20(4):201-202
No abstract available.
Humans
;
Uterine Cervical Neoplasms
4.Radiotherapy in Elderly Patients with Cancer.
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2011;29(1):1-10
Due to improved life spans, cancer incidence has increased with more aged patients presenting with cancer. Elderly cancer patients could have compromised organ function and/or comorbidities. Due to poor social support or lack of early diagnosis, treatment outcomes for elderly cancer patients are poor in general. However, with aggressive support during cancer management as well as careful selection, most elderly cancer patients can tolerate standard radiation therapy with good results based on published articles. Here, we reviewed existing articles regarding compliance and treatment results in elderly cancer patients based on tumor site.
Aged
;
Comorbidity
;
Compliance
;
Early Diagnosis
;
Humans
;
Incidence
5.Management for locally advanced cervical cancer: new trends and controversial issues
Radiation Oncology Journal 2018;36(4):254-264
This article reviewed new trends and controversial issues, including the intensification of chemotherapy and recent brachytherapy (BT) advances, and also reviewed recent consensuses from different societies on the management of locally advanced cervical cancer (LACC). Intensive chemotherapy during and after radiation therapy (RT) was not recommended as a standard treatment due to severe toxicities reported by several studies. The use of positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) for pelvic RT planning has increased the clinical utilization of intensity-modulated radiation therapy (IMRT) for the evaluation of pelvic lymph node metastasis and pelvic bone marrow. Recent RT techniques for LACC patients mainly aim to minimize toxicities by sparing the normal bladder and rectum tissues and shortening the overall treatment time by administering a simultaneous integrated boost for metastatic pelvic lymph node in pelvic IMRT followed by MRI-based image guided adaptive BT.
Bone Marrow
;
Brachytherapy
;
Consensus
;
Drug Therapy
;
Electrons
;
Humans
;
Lymph Nodes
;
Magnetic Resonance Imaging
;
Neoplasm Metastasis
;
Pelvic Bones
;
Radiotherapy, Intensity-Modulated
;
Rectum
;
Urinary Bladder
;
Uterine Cervical Neoplasms
6.Changes of Supportive Care Needs and Quality of Life in Patients with Breast Cancer.
Jin Hee PARK ; Mison CHUN ; Yong Sik JUNG ; Young Mi JUNG
Asian Oncology Nursing 2016;16(4):217-225
PURPOSE: The purpose of this study was to identify changes of supportive care needs and relationship to quality of life (QOL) in patients with breast cancer. METHODS: 117 patients with breast cancer were administered the Supportive Care Needs Survey-Short form 34 and the Functional Assessment of Cancer Therapy-Breast before adjuvant therapy after mastectomy (T1), at the end of completing adjuvant therapy (T2), as well as 6 months after the completion of adjuvant therapy (T3). Data were analyzed using SPSS/Win 21.0. RESULTS: The highest unmet supportive care needs were observed in the health system and information domain and the psychological domain at each time point. The health system and information (F=22.49, p<.001) and physical and daily living needs (F=5.72, p=.004) were higher at T1 and T2 than T3. The psychological (F=7.43, p=.001) and patient care and support needs were higher at T1 than T2 and T3. Multiple regression analysis showed that breast cancer patients with greater physical and daily living and psychological needs were significantly associated with poorer QOL at all times. CONCLUSION: Supportive care should be timely provided to breast cancer patients to improve their ability to cope with physical and psychological problem and QOL. Breast cancer patients who had more unmet needs in psychological and physical domains were more likely to have a poor QOL.
Breast Neoplasms*
;
Breast*
;
Humans
;
Mastectomy
;
Patient Care
;
Quality of Life*
7.Radiotherapy Results in Stage IIB Uterine Cervix Cancer.
Whoon Jong KIL ; Mison CHUN ; Seunghee KANG ; Young Taek OH ; Hee Sug RYU ; Hee Jae JU ; Eun Ju LEE
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2001;19(4):345-352
PURPOSE: To evaluate the treatment results and prognostic factors after radiotherapy in stage IIB uterine cervix cancer. MATERIALS AND METHODS: We retrospectively analyzed the records of 90 patients with stage IIB uterine cervix cancer who received radiotherapy between 9/94 and 12/99. Age was ranged from 28 to 79 years (median 57). Tumor size was > or = 4 cm in 64 patients. Preteatment SCC level was measured in 76 patients. Twenty nine patients received conventional radiotherapy (QD) and the others received modified hyperfractionated radiotherapy (BID). Only 7 patients in BID had tumor size <4 cm. All patients received high dose rate brachytherapy (4 Gy x 7 or 5 Gy x 6). No patient received concurrent chemotherapy during radiotherapy. Follow up period was ranging from 9 to 76 months (median 38). RESULTS: The 5-year overall and disease free survival rates were 73.4% and 71.6%, respectively. Local recurrences occurred in 10% of patients, and distant metastasis in 18.9%. There was a significant correlation between OS/DFS and tumor size (<4 cm; OS 95.2%, DFS 91.4%, > or = 4 cm; OS 63.4%, DFS 63.4%). Pretreatment SCC level was one of prognostic factors only in univariate analysis. CONCLUSION: With modified hyperfractionated radiotherapy, there was very low local recurrence rate (6.6%) and high 5-year overall and disease free survival rate (75.4% and 70.5%), which is comparable to results after concurrent chemoradiotherapy in bulky, locally advanced stage IIB uterine cervix cancer.
Brachytherapy
;
Cervix Uteri*
;
Chemoradiotherapy
;
Disease-Free Survival
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Humans
;
Neoplasm Metastasis
;
Radiotherapy*
;
Recurrence
;
Retrospective Studies
8.Conservative Split Course Radiation Therapy for Unresectable Stage III Non-Small Cell Lung Carcinoma with Poor Prognostic Factors.
Young Taek OH ; Mison CHUN ; Seung Hee KANG
Journal of Lung Cancer 2004;3(1):11-15
PURPOSE: Many studies for unresectable stage III non-small cell lung carcinomas (NSCLC) have focused on patients with good prognostic factors. However, there have been few reports on patients with poor prognostic factors. Herein, those patients with poor prognostic factors were treated with conservative split course radiation therapy (RT) alone, and the feasibility and survivals evaluated. Methods and Materials: Between Jan 1997 and Dec 2001, 73 patients started conservative split course RT. They were confirmed to have unresectable stage III NSCLC with poor prognostic factors; performance scale> or = ECOG 2 or weight loss> or =5% during the last 6 months. They initially received 30 Gy of radiation in 2.5 or 3 Gy per fractions to the gross tumor volume (GTV). The tumor response was evaluated 2~3 weeks later. A second course of RT was also recommended for good responders: > or =50% tumor diameter reduction or improved distal atelectasis. The treatment related toxicity was also evaluated. RESULTS: Nine patients failed to finish the initial course of RT (3~27 Gy) due to disease progression or personal reasons. Thirty-four (53.1%) of the 64 patients who completed the first course of RT showed a good tumor response. Twenty-seven good responders received the second course of RT, with a total of 51 to 60 Gy. Seven of these did not receive the second course of RT due to distant metastasis or poor performance. The two-year survival rate and median survival in all patients and in the 27 good responders who completed the second course of RT were 19.7% and 12 months and 30.3 and 20 months, respectively. Five (12.8%) of the 39 evaluable patients had grade III radiation esophagitis (N=1) or pneumonitis (N=4). Conclusions: Conservative split course RT was a tolerable and effective modality for unresectable stage III NSCLC with poor prognostic factors. In addition, it was able to produce relatively good survival results in patients showing a good response after the first course and who completed the second course of RT
Disease Progression
;
Esophagitis
;
Humans
;
Lung*
;
Neoplasm Metastasis
;
Pneumonia
;
Pulmonary Atelectasis
;
Survival Rate
;
Tumor Burden
9.High Dose Rate Interstitial Brachytherapy in Soft Tissue Sarcomas: Technical Aspect.
Mison CHUN ; Seunghee KANG ; Byoung Suck KIM ; Young Taek OH
The Journal of the Korean Society for Therapeutic Radiology and Oncology 1999;17(1):43-51
PURPOSE: To discuss the technical aspect of interstitial brachytherapy including method of implant, insertion time of radioactive source, total radiation dose, and complication, we reviewed patients who had diagnoses of soft tissue sarcoma and were treated by conservative surgery, interstitial implant and external beam radiation therapy. MATERIALS AND METHODS: Between May 1995 and Dec. 1997, ten patients with primary or recurrent soft tissue sarcoma underwent surgical resection (wide margin excision) and received radiotherapy including interstitial brachytherapy. Catheters were placed with regular intervals of 1~1.5 cm immediately after tumor removal and covering the critical structures, such as neurovascular bundle or bone, with gelform, muscle, or tissue expander in the cases where the tumors were close to those structures. Brachytherapy consisted of high dose rate, iridium-192 implant which delivered 12~15 Gy to 1 cm distance from the center of source axis with 2~2.5 Gy/fraction, twice a day, starting on 6th day after the surgery. Within one month after the surgery, total dose of 50~55 Gy was delivered to the tumor bed with wide margin by the external beam radiotherapy. RESULTS: All patients completed planned interstitial brachytherapy without acute side effects directly related with catheter implantation such as infection or bleeding. With median follow up duration of 25 months (range 12~41 months), no local recurrences were observed. And there was no severe form of chronic complication (RTOG/EORTC grade 3 or 4). CONCLUSION: The high dose rate interstitial brachytherapy is easy and safe way to minimize the radiation dose delivered to the adjacent normal tissue and to decrease radiation induced chronic morbidity such as fibrosis by reducing the total dose of external radiotherapy in the management of soft tissue sarcoma with conservative surgery.
Axis, Cervical Vertebra
;
Brachytherapy*
;
Catheters
;
Diagnosis
;
Fibrosis
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Radiotherapy
;
Recurrence
;
Sarcoma*
;
Tissue Expansion Devices
10.CT-based quantitative evaluation of radiation-induced lung fibrosis: a study of interobserver and intraobserver variations.
Jaesung HEO ; Oyeon CHO ; O Kyu NOH ; Young Taek OH ; Mison CHUN ; Mi Hwa KIM ; Hae Jin PARK
Radiation Oncology Journal 2014;32(1):43-47
PURPOSE: The degree of radiation-induced lung fibrosis (RILF) can be measured quantitatively by fibrosis volume (VF) on chest computed tomography (CT) scan. The purpose of this study was to investigate the interobserver and intraobserver variability in CT-based measurement of VF. MATERIALS AND METHODS: We selected 10 non-small cell lung cancer patients developed with RILF after postoperative radiation therapy (PORT) and delineated VF on the follow-up chest CT scanned at more than 6 months after radiotherapy. Three radiation oncologists independently delineated VF to investigate the interobserver variability. Three times of delineation of VF was performed by two radiation oncologists for the analysis of intraobserver variability. We analysed the concordance index (CI) and inter/intraclass correlation coefficient (ICC). RESULTS: The median CI was 0.61 (range, 0.44 to 0.68) for interobserver variability and the median CIs for intraobserver variability were 0.69 (range, 0.65 to 0.79) and 0.61(range, 0.55 to 0.65) by two observers. The ICC for interobserver variability was 0.974 (p < 0.001) and ICCs for intraobserver variability were 0.996 (p < 0.001) and 0.991 (p < 0.001), respectively. CONCLUSION: CT-based measurement of VF with patients who received PORT was a highly consistent and reproducible quantitative method between and within observers.
Carcinoma, Non-Small-Cell Lung
;
Evaluation Studies as Topic*
;
Fibrosis*
;
Follow-Up Studies
;
Humans
;
Lung*
;
Observer Variation*
;
Radiotherapy
;
Thorax
;
Tomography, X-Ray Computed